Status:

TERMINATED

Study of WA-NG (NG-IMT) Telescope Prosthesis in Patients With End-stage Age-related Macular Degeneration

Lead Sponsor:

VisionCare, Inc.

Conditions:

Age Related Macular Degeneration

Eligibility:

All Genders

65+ years

Phase:

NA

Brief Summary

The purpose of this study is to evaluate the safety of the updated Model WA-NG telescope prosthesis (hereafter WA-NG telescope), an injectable telescope device, in patients with bilateral moderate to ...

Detailed Description

Patients will be screened for eligibility and informed consent will be obtained from those who meet screening criteria and are interested in participating in the study. Eligible patients will be exami...

Eligibility Criteria

Inclusion

  • \*\*The following Inc. \& Exc. are sample and not completed list \*\*
  • Main Exclusion Criteria:
  • Patients with bilateral, stable, moderate to profound central vision impairment due to bilateral central scotoma associated with end-stage macular degeneration, defined as retinal findings of bilateral, geographic atrophy or disciform scar with foveal involvement.
  • Patients must have distance BCVA between 20/80 and 20/800, and adequate peripheral vision in one eye (the non-implanted eye) to allow navigation
  • Patients must achieve at least a five letter improvement on the ETDRS chart in the eye scheduled for surgery, with the external telescope simulator (ETS)
  • Patients must be available for the study duration of 12 months
  • Patients must be alert, mentally competent, and able to understand and comply with the requirements of the clinical trial, and be personally motivated to abide by the requirements and restrictions of the clinical trial.
  • Main Exclusion Criteria:
  • Evidence of active CNV on fluorescein angiography or treatment for CNV within the past six months.
  • Patients who may require fellow eye cataract extraction and intraocular lens implantation during the 12 months following WA-NG telescope implantation. If fellow eye cataract extraction is anticipated, this procedure should be performed at least 30 days prior to enrollment in the clinical study.
  • Patients who have had or are expected to have ophthalmic related surgery within the 30 days preceding implantation of the device.
  • Patients who have undergone previous intraocular or corneal surgery of any kind in the operative eye(s), including any type of surgery for either refractive or therapeutic purposes.
  • Patients participating in any other ophthalmic drug or device clinical trial during the time of this clinical investigation

Exclusion

    Key Trial Info

    Start Date :

    May 1 2015

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    July 1 2020

    Estimated Enrollment :

    9 Patients enrolled

    Trial Details

    Trial ID

    NCT04468373

    Start Date

    May 1 2015

    End Date

    July 1 2020

    Last Update

    July 13 2020

    Active Locations (2)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (2 locations)

    1

    Mater Private Hospital

    Dublin, Ireland

    2

    VISSUM Ophthalmological Corporation

    Alicante, Spain